65th ASH Annual Meeting & Exposition: ASH Poster Walk on Diversity, Equity and Inclusion(DEI) in Hematology

ASH Poster Walks

Research, Biological therapies, Clinical Practice (Health Services and Quality), Non-Biological therapies, Clinical Research, health outcomes research, Workforce, Diversity, Equity, and Inclusion (DEI) , health disparities research, drug development, real-world evidence, Therapies, Study Population, Human

(Virtual Program)

This poster walk will highlight works that investigate structural barriers impacting provision of care across hematology for patients from underserved racial/ ethnic groups, those of lower socio-economic status, and other vulnerable groups. In particular, the poster walk will spotlight research that advances efforts to diversify patient populations, mitigate barriers to care, and maximize the equitable provision of optimal care for marginalized or under-privileged groups. The walk will also feature posters outlining work being done to make our field more inclusive for patients, donors, and caregivers, as well as for practitioners across the hematology workforce. It will serve to connect stakeholders in Diversity, Equity, and Inclusion (DEI) in hematology, and facilitate discussions on the state of DEI research in the field. This walk is well aligned with ASH Research Agenda to advance equity both in the U.S. and globally.

Health Insurance Continuity Is Associated with Stage at Diagnosis Among Children, Adolescents, and Young Adults Newly Diagnosed with Lymphoma

Xu Ji, PhD, MSPH

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA

1084

Evaluating Sex-Based Hemoglobin Reference Intervals Using Strict Definitions of Health

Lauren E. Merz, MD, MSc^1,2, Alexander Chaitoff, MD, MPH³^*, Angela C Weyand, MD⁴, Michael Fralick, MD, PhD⁵^* and Michelle Sholzberg, MDCM, MSc⁶

¹Mass General Brigham, Boston
²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
⁴Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI
⁵University of Toronto, Toronto, ON, Canada
⁶Division of Hematology-Oncology, St. Michael's Hospital, Toronto, ON, Canada

3905

Neighborhood Disadvantage Increases Risk of Adverse Clinical Events in Children with Sickle Cell Disease

Ijele Adimora, MD, MBA¹, Luisanna M Sanchez Ventura, MD² and Jonathan M. Flanagan, PhD²

¹The Johns Hopkins University School of Medicine, Baltimore, MD
²Texas Children's Cancer & Hematology Center, Baylor College of Medicine, Houston, TX

2350

Transportation Cost Is a Significant Barrier to Quality Care for Hematologic Malignancy Patients in a Minority-Rich, Socioeconomically Disadvantaged Population

Lauren Laufer, MS, BA¹, Lemchukwu Amaeshi, MD², Alex Sisto, MD³^*, Kateryna Fedorov, MD^4,5, Rosmi Mathew⁶^*, David Levitz, MD⁵, Ioannis Mantzaris⁵, Noah Kornblum, MD⁵, Mendel Goldfinger, MD⁵^*, Alejandro Sica, MD⁵^*, Dennis L Cooper, MD⁵, Marina Y. Konopleva^5,7, Bruce Rapkin⁶^*, Amit Verma, MD⁸, Aditi Shastri, MD⁹ and Nishi Shah, MBBS, MPH⁵

¹Albert Einstein College Of Medicine/Montefiore Medical Center, Bronx, NY
²Montefiore Medical Center, Bronx, NY
³Montefiore Medical Center and Albert Einstein College of Medicine, Bronx
⁴Oncology, Vanderbilt University Medical Center, Nashville, NY
⁵Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
⁶Montefiore Medical Center, Bronx
⁷Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁸Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
⁹Blood Cancer Institute, Department of Oncology, Albert Einstein College of Medicine, Bronx, NY

2384

Establishing a Sociodemographic Data Banking Study in Patients with Hematologic Disorders – a Feasibility Assessment

Morohuntodun O. Oni^1,2^*, Alexandria Hawkins, BS^2,3^*, Emily Stein^2,4^*, Steven G. Dubois, MD, MS^2,3,5^*, Katie A. Greenzang, MD, EdM^2,3,5,6^*, Rahela Aziz-Bose, MD^2,3,5,6, Christine Duncan, MD^2,3,5, Allison F. O'Neill, MD^2,3,5^*, Andrew E. Place, MD, PhD^2,3,5, Puja J. Umaretiya, MD^2,3,5,6^*, Natasha Archer, MD^2,5,7 and Kira Bona, MD, MPH^2,3,5,6

¹Dana-Farber / Boston Children’s Cancer and Blood Disorders Center, Brookline, MA
²Division of Pediatric Hematology/Oncology, Boston Children’s Hospital, Boston, MA
³Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Dana-Farber / Boston Children’s Cancer and Blood Disorders Center, Boston, MA
⁵Department of Pediatrics, Harvard Medical School, Boston, MA
⁶Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA
⁷Dana-Farber/Boston Children's Cancer and Blood Disorder Ctr., Boston, MA

3758

Racial Discrepancies in the Use of Stigmatizing Language Is Evident in Hematology/Oncology Electronic Medical Records

Zalaya K Ivy, MD, MS¹, Sharon Hwee, MPH²^*, Brittany C Kimball, MD³, Michael D Evans, MS¹^*, Catherine M Bendel, MD⁴^* and Alex A Boucher, MD¹

¹University of Minnesota, Minneapolis, MN
²University of Minnesota/Masonic Cancer Center, Minneapolis, MN
³Division of Hematology/Oncology, Mayo Clinic College of Medicine and Science, Rochester, MN
⁴Department of Pediatrics, Division of Neonatology, University of Minnesota Medical School, Minneapolis, MN

See more of: ASH Poster Walks

<< Previous Poster Walk Application | Next Poster Walk Application >>